Header Logo

Connection

VINCENT TAM to Male

Back to Details
This is a "connection" page, showing publications VINCENT TAM has written about Male.
VINCENT TAM
Connection Strength
0.739
Male
  1. Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. J Infect Dis. 2025 Jul 30; 232(1):191-198.
    View in: PubMed
    Score: 0.038
  2. Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity. Antimicrob Agents Chemother. 2025 08 06; 69(8):e0028725.
    View in: PubMed
    Score: 0.038
  3. Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023 10 03; 78(10):2435-2441.
    View in: PubMed
    Score: 0.034
  4. Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii. Virulence. 2022 Dec; 13(1):1920-1927.
    View in: PubMed
    Score: 0.032
  5. Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597.
    View in: PubMed
    Score: 0.028
  6. Validation of Vancomycin Dosing Guidance During Transition of Care. J Clin Pharmacol. 2021 06; 61(6):806-809.
    View in: PubMed
    Score: 0.028
  7. Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. Antimicrob Agents Chemother. 2020 02 21; 64(3).
    View in: PubMed
    Score: 0.026
  8. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019 Apr; 93(4):346-348.
    View in: PubMed
    Score: 0.024
  9. Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 09; 104(3):534-538.
    View in: PubMed
    Score: 0.023
  10. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 01; 61(1).
    View in: PubMed
    Score: 0.021
  11. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 11; 60(11):6980-6982.
    View in: PubMed
    Score: 0.021
  12. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 12; 71(12):3585-3587.
    View in: PubMed
    Score: 0.021
  13. Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2016 Feb; 84(2):155-8.
    View in: PubMed
    Score: 0.019
  14. Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother. 2015 May; 59(5):2930-3.
    View in: PubMed
    Score: 0.019
  15. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015; 70(6):1903-7.
    View in: PubMed
    Score: 0.018
  16. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4.
    View in: PubMed
    Score: 0.018
  17. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8.
    View in: PubMed
    Score: 0.018
  18. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014 Sep; 69(9):2517-21.
    View in: PubMed
    Score: 0.018
  19. Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion. Int J Antimicrob Agents. 2014 Feb; 43(2):197-9.
    View in: PubMed
    Score: 0.017
  20. A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012 Jan; 72(1):97-102.
    View in: PubMed
    Score: 0.015
  21. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 2011 May; 52(10):1280-1.
    View in: PubMed
    Score: 0.014
  22. Emergence of KPC-producing Klebsiella pneumoniae in Texas. Diagn Microbiol Infect Dis. 2011 Feb; 69(2):234-5.
    View in: PubMed
    Score: 0.014
  23. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009 Dec; 34(6):570-4.
    View in: PubMed
    Score: 0.013
  24. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
    View in: PubMed
    Score: 0.012
  25. Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singap. 2008 Oct; 37(10):826-30.
    View in: PubMed
    Score: 0.012
  26. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
    View in: PubMed
    Score: 0.011
  27. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Feb; 60(2):163-7.
    View in: PubMed
    Score: 0.011
  28. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.
    View in: PubMed
    Score: 0.011
  29. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis. 2007 May; 58(1):99-104.
    View in: PubMed
    Score: 0.011
  30. Protection against vancomycin-associated nephrotoxicity by zileuton: role of mitochondria revealed by electron microscopic study. Ultrastruct Pathol. 2025; 49(5):414-420.
    View in: PubMed
    Score: 0.010
  31. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005 Sep 01; 41(5):754-7.
    View in: PubMed
    Score: 0.010
  32. Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection. Antimicrob Agents Chemother. 2024 11 06; 68(11):e0089824.
    View in: PubMed
    Score: 0.009
  33. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003 Jun; 47(6):1853-61.
    View in: PubMed
    Score: 0.008
  34. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003 Mar; 23(3):291-5.
    View in: PubMed
    Score: 0.008
  35. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002 Sep; 50(3):425-8.
    View in: PubMed
    Score: 0.008
  36. Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats. Elife. 2021 07 01; 10.
    View in: PubMed
    Score: 0.007
  37. Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review. Pharmacotherapy. 2000 Sep; 20(9):1116-9.
    View in: PubMed
    Score: 0.007
  38. Plasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease. Med J Malaysia. 2019 06; 74(3):209-214.
    View in: PubMed
    Score: 0.006
  39. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques. Antimicrob Agents Chemother. 2017 08; 61(8).
    View in: PubMed
    Score: 0.005
  40. Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. Antimicrob Agents Chemother. 2017 07; 61(7).
    View in: PubMed
    Score: 0.005
  41. Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. Antimicrob Agents Chemother. 2017 06; 61(6).
    View in: PubMed
    Score: 0.005
  42. Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017 Feb; 29(1):25-29.
    View in: PubMed
    Score: 0.005
  43. Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake. PLoS One. 2016; 11(3):e0150270.
    View in: PubMed
    Score: 0.005
  44. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother. 2016 Mar; 71(3):727-30.
    View in: PubMed
    Score: 0.005
  45. Enrichment of committed human nucleus pulposus cells expressing chondroitin sulfate proteoglycans under alginate encapsulation. Osteoarthritis Cartilage. 2015 Jul; 23(7):1194-203.
    View in: PubMed
    Score: 0.005
  46. Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer. 2015 Jan; 62(1):80-4.
    View in: PubMed
    Score: 0.005
  47. Development and validation of a highly sensitive LC-MS/MS assay for the quantification of arginine vasopressin in human plasma and urine: Application in preterm neonates and child. J Pharm Biomed Anal. 2014 Oct; 99:67-73.
    View in: PubMed
    Score: 0.004
  48. Liver function in rats acclimatized to a simulated altitude of 5500 m. High Alt Med Biol. 2013 Dec; 14(4):375-82.
    View in: PubMed
    Score: 0.004
  49. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.
    View in: PubMed
    Score: 0.004
  50. A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERa protein. Carcinogenesis. 2012 May; 33(5):1089-97.
    View in: PubMed
    Score: 0.004
  51. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15; 51(12):1406-10.
    View in: PubMed
    Score: 0.003
  52. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm. 2009 Nov-Dec; 6(6):1703-15.
    View in: PubMed
    Score: 0.003
  53. Significant publications on infectious diseases pharmacotherapy in 2007. Am J Health Syst Pharm. 2008 Nov 15; 65(22):e72-9.
    View in: PubMed
    Score: 0.003
  54. Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metab Dispos. 2006 Nov; 34(11):1837-48.
    View in: PubMed
    Score: 0.003
  55. Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients. J Chemother. 2006 Aug; 18(4):402-8.
    View in: PubMed
    Score: 0.003
  56. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006 Mar; 54(3):223-30.
    View in: PubMed
    Score: 0.002
  57. Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. Drug Metab Dispos. 2005 Dec; 33(12):1777-84.
    View in: PubMed
    Score: 0.002
  58. Subcutaneous administration of cefepime. J Pain Symptom Manage. 2005 Aug; 30(2):170-4.
    View in: PubMed
    Score: 0.002
  59. Disposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy. 2003 Mar; 23(3):310-4.
    View in: PubMed
    Score: 0.002
  60. Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review. Pharmacotherapy. 2001 Aug; 21(8):998-1002.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.